Navigation Links
NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
Date:7/23/2008

rol, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-Q for the three months ended March 31, 2008. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Important Additional Information

A special meeting of NxStage stockholders will be held on Thursday, July 31, 2008 to obtain stockholder approval for the second closing of a $43 million private placement in NxStage. In connection with the private placement and required stockholder approval, NxStage filed with the SEC a definitive proxy statement on July 8, 2008. This proxy statement was mailed to NxStage's stockholders on or about July 9, 2008. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT NXSTAGE AND THE PRIVATE PLACEMENT. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC's website at http://www.sec.gov, at NxStage's website at http://www.nxstage.com or by writing to NxStage Medical
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
2. NxStage Medical Provides Update on Medisystems Acquisition
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. NxStage Medical Announces Needle Supply Agreement with DaVita
7. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
8. NxStage Medical to Present at William Blair Growth Stock Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... Health Care Forum discusses the future of Continuing ... ... Accredited online nursing courses,are replacing traditional classroom-based courses, offering nurses ... options., Ann Johnson, CEO of Wild Iris Medical Education took ...
... 2 Simbionix has announced the,release of a ... simulator that,gives trainees hands-on experience with different techniques ... tubal,sterilization and oophorectomy., The GYN module is ... developed for the LAP Mentor, the world,s most ...
... Japan and UNION CITY, Calif., June 2 ... that the two,companies have entered into a research ... and Asian development and,commercialization of sirolimus for the ... related macular degeneration (wet AMD) and,diabetic macular edema ...
Cached Biology Technology:Modernizing Continuing Education With Online Courses 2Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level 2Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 2Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions 3
(Date:8/27/2014)... has shown that piglets can be weaned later with ... outcome of the study at the University,s Roseworthy campus, ... is an important finding for pig producers. It allows ... production. , "Sows don,t usually start their oestrous cycles ... piglets have been weaned," says Ms Alice Weaver, PhD ...
(Date:8/27/2014)... finds , Gamblers show the same tendencies as ... shown. , Researchers, led by Dr Elliot Ludvig of ... that found that both human gamblers and pigeons were ... rewards. , Published in Biology Letters , the ... role that memories of previous biggest wins and losses ...
(Date:8/26/2014)... Like a protective tent over a colony of ... infections especially difficult. Microorganisms protected in a biofilm ... antibiotic resistance and recalcitrance to treatment, and biofilm-protected ... bacterial infections in humans and are 50 to ... bacterial infections. , "In essence, we may have ...
Breaking Biology News(10 mins):Piglet weaning age no bar to litter frequency 2Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... MARC (Maximizing Access to Research Careers) Program has announced ... Conferences held in July, 2013. These awards are meant ... and scientists into the mainstream of the basic science ... at the FASEB Science Research Conferences. This year MARC ...
... MARC (Maximizing Access to Research Careers) Program has announced ... Study of Reproduction meeting in Montreal, Canada from July ... entry of students, postdoctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ...
... 2011 and 2012, research from China,s Nanjing University made ... of genetic material from the plants they,d ingested could ... animals, own genes off. The surprising results from Chen-Yu ... one day be treated with medicinal food, but also ...
Cached Biology News:Hold the medicinal lettuce 2Hold the medicinal lettuce 3
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: